Clinical Trial Update: Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing continuing lamivudine versus switching to entecavir in patients with chronic hepatitis B and detectable HBV DNA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ENTECAVIR (ENTECAVIR)
• Lamivudine (lamivudine)

Snippet

Sponsor: Yonsei University | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED